Amiodarone to prevent recurrence of atrial fibrillation

New England Journal of Medicine

Volumn 342, Issue 13, 2000, Pages 913-920

  Roy, Denis ^a   Talajic, Mario ^a   Dorian, Paul ^b   Connolly, Stuart ^c   Eisenberg, Mark J ^a   Green, Martin ^d   Kus, Teresa ^e   Lambert, Jean ^a   Dubuc, Marc ^a   Gagné, Pierre ^a   Nattel, Stanley ^a   Thibault, Bernard ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^e HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; PROPAFENONE; SOTALOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; TREATMENT OUTCOME;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPAFENONE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; SOTALOL;

EID: 0007356262     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200003303421302     Document Type: Article

References (40)

1. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med 1982;306:1018-22.
2. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995;155:469-73.
3. Braunwald E. Shattuck Lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360-9.
4. Morris JJ Jr, Entman M, North WC, Kong Y, McIntosh H. The changes in cardiac output with reversion of atrial fibrillation to sinus rhythm. Circulation 1965;31:670-8.
5. Shapiro W, Klein G. Alterations in cardiac function immediately following electrical conversion of atrial fibrillation to normal sinus rhythm. Circulation 1968;38:1074-84.
6. Lewis RV, Irvine N, McDevitt DG. Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. Eur Heart J 1988;9:777-81,
7. Gosselink ATM, Crijns HJGM, van den Berg MP. Functional capacity before and after cardioversion of atrial fibrillation: a controlled study. Br Heart J 1994;72:161-6.
8. Pritchett ELC. Management of atrial fibrillation. N Engl J Med 1992; 326:1264-71.
9. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
10. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57. [Erratum, Arch Intern Med 1994; 154:2254.]
11. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990; 82:1106-16. [Erratum, Circulation 1991;83:714.]
12. Dethy M, Chassat C, Roy D, Mercier L-A. Doppler echocardiographic predictors of recurrence of atrial fibrillation after cardioversion. Am J Cardiol 1988;62:723-6.
13. Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991;68:41-6.
14. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990;82:1932-9.
15. Connolly SJ, Hoffert DL. Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol 1989;63:817-9.
16. Pritchett ELC, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias: a randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med 1991;114:539-44.
17. Antman EM, Beamer AD, Cantillon C, McGowan N, Goldman L, Friedman PL. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988;12:1005-11. [Erratum, J Am Coll Cardiol 1989;13:264.]
18. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993;71:558-63.
19. Van Gelder IC, Crijns HJGM, Van Gilst WH, Van Wijk LM, Hamer HPM, Lie KI. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989;64:1317-21.
20. Anderson JL, Gilbert EM, Alpert BL, et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: a multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989;80: 1557-70.
21. Naccarelli GV, Dorian P, Hohnloser SH, Coumel P. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am J Cardiol 1996;77:A53-A59.
22. Nattel S, Hadjis T, Talajic M. The treatment of atrial fibrillation: an evaluation of drug therapy, electrical modalities and therapeutic considerations. Drugs 1994;48:345-71.
23. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-32.
24. Middlekauff HR, Wiener I, Stevenson WG. Low-dose amiodarone for atrial fibrillation. Am J Cardiol 1993;72:75F-81F.
25. Vitolo E, Tronci M, Larovere MT, Rumolo R, Morabito A. Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol 1981;36:431-44.
26. Gosselink AT, Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld ACP, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992;267:3289-93.
27. Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50.
28. Zarembski DG, Nolan PE Jr, Slack MK, Caruso AC. Treatment of resistant atrial fibrillation: a meta-analysis comparing amiodarone and flecainide. Arch Intern Med 1995;155:1885-91.
29. Kochiadakis GE, Igoumenidis NE, Marketou ME, Solomou MC, Kanoupakis EM, Vardas PE. Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1998;81: 995-8.
30. Roy D, Talajic M, Thibault B, et al. Pilot study and protocol of the Canadian Trial of Atrial Fibrillation (CTAF). Am J Cardiol 1997;80:464-8.
31. Talajic M, MacDonald RG, Nattel S. Restoration of sinus rhythm in patients with atrial fibrillation. Can J Cardiol 1996;12:Suppl A:29A-35A.
32. Hinkle LE Jr, Thaler HT. Clinical classification of cardiac deaths. Circulation 1982;65:457-64.
33. Mantel M. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
34. Cox DR. Regression models and life tables. J R Stat Soc [B] 1972;34: 187-220.
35. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997;30:791-8.
36. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997;350:1417-24.
37. Mason JW. Amiodarone. N Engl J Med 1987;316:455-66.
38. Collaborative Group for Amiodarone Evaluation. Multicenter controlled observation of a low-dose regimen of amiodarone for treatment of severe ventricular arrhythmias. Am J Cardiol 1984;53:1564-9.
39. Raeder EA, Podrid PJ, Lown B. Side effects and complications of amiodarone therapy. Am Heart J 1985;109:975-83.
40. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA 1993;270:1589-95.